Corvus Pharmaceuticals Inc (NASDAQ: CRVS) on Tuesday, soared 2.51% from the previous trading day, before settling in for the closing price of $7.56. Within the past 52 weeks, CRVS’s price has moved between $1.05 and $7.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 25.45%. With a float of $50.12 million, this company’s outstanding shares have now reached $62.55 million.
The extent of productivity of a business whose workforce counts for 28 workers is very important to gauge. In terms of profitability, gross margin is 58.54%, operating margin of -9511.79%, and the pretax margin is -9193.5%.
Corvus Pharmaceuticals Inc (CRVS) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Corvus Pharmaceuticals Inc is 19.87%, while institutional ownership is 27.92%. The most recent insider transaction that took place on May 06 ’24, was worth 34,624. In this transaction an insider of this company bought 20,000 shares at a rate of $1.73, taking the stock ownership to the 153,773 shares. Before that another transaction happened on May 06 ’24, when Company’s President and CEO bought 577,634 for $1.73, making the entire transaction worth $1,000,000. This insider now owns 577,634 shares in total.
Corvus Pharmaceuticals Inc (CRVS) Performance Highlights and Predictions
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.12 earnings per share (EPS) for the period topping the consensus outlook (set at -0.12) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.45% per share during the next fiscal year.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Trading Performance Indicators
Corvus Pharmaceuticals Inc (CRVS) is currently performing well based on its current performance indicators. A quick ratio of 3.62 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.48 in one year’s time.
Technical Analysis of Corvus Pharmaceuticals Inc (CRVS)
The latest stats from [Corvus Pharmaceuticals Inc, CRVS] show that its last 5-days average volume of 1.01 million was superior to 0.3 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 83.43%. Additionally, its Average True Range was 0.52.
During the past 100 days, Corvus Pharmaceuticals Inc’s (CRVS) raw stochastic average was set at 91.19%, which indicates a significant increase from 81.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.78% in the past 14 days, which was lower than the 84.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.16, while its 200-day Moving Average is $2.84. Now, the first resistance to watch is $8.20. This is followed by the second major resistance level at $8.65. The third major resistance level sits at $8.97. If the price goes on to break the first support level at $7.43, it is likely to go to the next support level at $7.11. Assuming the price breaks the second support level, the third support level stands at $6.66.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Key Stats
Market capitalization of the company is 484.76 million based on 62,551K outstanding shares. Right now, sales total 0 K and income totals -27,030 K. The company made 0 K in profit during its latest quarter, and -4,260 K in sales during its previous quarter.
